These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 27735905

  • 21. Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial).
    Boiko AN, Batysheva TT, Minaeva NG, Babina LA, Vdovichenko TV, Zhuravleva EY, Shikhkerimov RK, Malykhina EA, Khozova AA, Zaitsev KA, Kostenko EV.
    Neurosci Behav Physiol; 2008 Nov; 38(9):933-6. PubMed ID: 18975095
    [Abstract] [Full Text] [Related]

  • 22. Wearable Sensors for Advanced Therapy Referral in Parkinson's Disease.
    Heldman DA, Giuffrida JP, Cubo E.
    J Parkinsons Dis; 2016 Jul 02; 6(3):631-8. PubMed ID: 27392872
    [Abstract] [Full Text] [Related]

  • 23. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE, Sydow O, Johansson A, Nyholm D, Holmberg B, Widner H, Dizdar N, Linder J, Hauge T, Jansson R, Bergmann L, Kjellander S, Marshall TS.
    Parkinsonism Relat Disord; 2016 Aug 02; 29():17-23. PubMed ID: 27318707
    [Abstract] [Full Text] [Related]

  • 24. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
    Martínez-Martín P, Hernández B, Ricart J, FAST Study Group.
    Neurologia; 2014 Apr 02; 29(3):153-60. PubMed ID: 23465686
    [Abstract] [Full Text] [Related]

  • 25. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
    Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L, Pezzoli G.
    Mov Disord; 2007 Jun 15; 22(8):1145-9. PubMed ID: 17661426
    [Abstract] [Full Text] [Related]

  • 26. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
    Marras C, Lang A, Krahn M, Tomlinson G, Naglie G, Parkinson Study Group.
    Mov Disord; 2004 Jan 15; 19(1):22-8. PubMed ID: 14743356
    [Abstract] [Full Text] [Related]

  • 27. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov 15; 11(135):101-6. PubMed ID: 24165688
    [Abstract] [Full Text] [Related]

  • 28. Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease.
    Timpka J, Fox T, Fox K, Honig H, Odin P, Martinez-Martin P, Antonini A, Chaudhuri KR.
    Acta Neurol Scand; 2016 Jun 15; 133(6):451-8. PubMed ID: 26358227
    [Abstract] [Full Text] [Related]

  • 29. [Treatment of non-motor fluctuations with combined drug stalevo in patients with Parkinson's disease].
    Levin OS, Ivanov AK, Shindriaeva NN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011 Jun 15; 111(1):38-42. PubMed ID: 21350410
    [Abstract] [Full Text] [Related]

  • 30. Motor profile and drug treatment of nursing home residents with Parkinson's disease.
    Weerkamp NJ, Zuidema SU, Tissingh G, Poels PJ, Munneke M, Koopmans RT, Bloem BR.
    J Am Geriatr Soc; 2012 Dec 15; 60(12):2277-82. PubMed ID: 23231550
    [Abstract] [Full Text] [Related]

  • 31. [The use of stalevo in the treatment of patients with Parkinson's disease].
    Kretova AS, Lyubimov AV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014 Dec 15; 114(10):35-8. PubMed ID: 25591514
    [Abstract] [Full Text] [Related]

  • 32. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR.
    Mov Disord; 2009 Jul 30; 24(10):1468-74. PubMed ID: 19425079
    [Abstract] [Full Text] [Related]

  • 33. [Stalevo (levodopa/carbidopa/entacapon)--a new generation drug in the treatment of Parkinson's disease].
    Fedorova NV, Levin OS, Smolentseva IG, Kulua TK.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006 Jul 30; 106(9):39-46. PubMed ID: 17069061
    [Abstract] [Full Text] [Related]

  • 34. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
    Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ.
    Mov Disord; 2015 Apr 30; 30(4):500-9. PubMed ID: 25545465
    [Abstract] [Full Text] [Related]

  • 35. Long-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's disease.
    Valldeoriola F, Grandas F, Santos-García D, Regidor I, Catalán MJ, Arbelo JM, Puente V, Mir P, Parra JC.
    Neurodegener Dis Manag; 2016 Aug 30; 6(4):289-98. PubMed ID: 27440190
    [Abstract] [Full Text] [Related]

  • 36. Duodopa® treatment for advanced Parkinson's disease: a review of efficacy and safety.
    Nyholm D.
    Parkinsonism Relat Disord; 2012 Sep 30; 18(8):916-29. PubMed ID: 22824056
    [Abstract] [Full Text] [Related]

  • 37. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
    Fernandez HH, Odin P.
    Curr Med Res Opin; 2011 May 30; 27(5):907-19. PubMed ID: 21351823
    [Abstract] [Full Text] [Related]

  • 38. [Nocturnal symptoms of Parkinson's disease and approaches to their correction].
    Kulua TK, Fedorova NV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013 May 30; 113(12):62-6. PubMed ID: 24430037
    [Abstract] [Full Text] [Related]

  • 39. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
    Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, GLORIA study investigators and coordinators.
    Parkinsonism Relat Disord; 2015 Mar 30; 21(3):231-5. PubMed ID: 25585993
    [Abstract] [Full Text] [Related]

  • 40. Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.
    Greig SL, McKeage K.
    CNS Drugs; 2016 Jan 30; 30(1):79-90. PubMed ID: 26692288
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.